Expert commentary
Michael Alosco, the study's senior author and co-director of clinical research at the CTE Center at Boston University, said:
"If this finding holds up with future research, it opens up a lot of doors."
Alosco also said:
"We still have more work to do before you can bring it back to patients."
And:
"But it's an exciting first step."
Michael Buckland, a clinical associate professor of pathology at the University of Sydney in Australia who was not involved in either study, said:
"It is a watershed moment for the field, demonstrating that fluid biomarkers can work in assisting diagnosis of CTE in the living."
Buckland also said:
"A confident CTE diagnosis in the living opens the door for clinical trials to start finding treatments for the disease."
And:
"While there is still a long way to go before the test can be validated for clinical use, it is remarkable to see how fast the field is moving."